HK1153938A1 - Use of a cdk inhibitor for the treatment of glioma cdk - Google Patents

Use of a cdk inhibitor for the treatment of glioma cdk

Info

Publication number
HK1153938A1
HK1153938A1 HK11108251.4A HK11108251A HK1153938A1 HK 1153938 A1 HK1153938 A1 HK 1153938A1 HK 11108251 A HK11108251 A HK 11108251A HK 1153938 A1 HK1153938 A1 HK 1153938A1
Authority
HK
Hong Kong
Prior art keywords
cdk
glioma
treatment
inhibitor
cdk inhibitor
Prior art date
Application number
HK11108251.4A
Other languages
English (en)
Chinese (zh)
Inventor
．塞歐梅
．法歐倫逖尼
．派森逖
Original Assignee
內爾維阿諾醫學科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 內爾維阿諾醫學科學有限公司 filed Critical 內爾維阿諾醫學科學有限公司
Publication of HK1153938A1 publication Critical patent/HK1153938A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK11108251.4A 2008-07-29 2011-08-08 Use of a cdk inhibitor for the treatment of glioma cdk HK1153938A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161323 2008-07-29
PCT/EP2009/059747 WO2010012733A1 (en) 2008-07-29 2009-07-28 Use of a cdk inhibitor for the treatment of glioma

Publications (1)

Publication Number Publication Date
HK1153938A1 true HK1153938A1 (en) 2012-04-13

Family

ID=41060058

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108251.4A HK1153938A1 (en) 2008-07-29 2011-08-08 Use of a cdk inhibitor for the treatment of glioma cdk

Country Status (7)

Country Link
US (1) US8946226B2 (xx)
EP (1) EP2323664B1 (xx)
JP (1) JP5677296B2 (xx)
CN (1) CN102105151B (xx)
ES (1) ES2532732T3 (xx)
HK (1) HK1153938A1 (xx)
WO (1) WO2010012733A1 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
TWI577680B (zh) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
JP2012509859A (ja) * 2008-11-24 2012-04-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 中皮腫の治療のためのｃｄｋ阻害物質
ES2660146T3 (es) * 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2534335T3 (es) 2010-05-20 2015-04-21 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la Trk cinasa
ES2602791T3 (es) * 2011-01-26 2017-02-22 Nerviano Medical Sciences S.R.L. Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa
WO2012101029A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
CN115813902A (zh) 2012-01-20 2023-03-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
EP2934564B1 (en) * 2012-12-20 2018-05-23 Lantmännen AS-Faktor AB Antisecretory factor (af) for use in the treatment of glioblastoma
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
CN107849615A (zh) 2015-06-01 2018-03-27 洛克索肿瘤学股份有限公司 诊断和治疗癌症的方法
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
MX2018005087A (es) 2015-10-26 2019-05-16 Loxo Oncology Inc Mutaciones puntuales en cáncer resistente a trk y métodos relacionados con las mismas.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2751636C2 (ru) 2016-04-04 2021-07-15 Локсо Онколоджи, Инк. Способы лечения детских раковых заболеваний
JP7061602B2 (ja) 2016-04-04 2022-04-28 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）－ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの液体製剤
DK3458456T3 (da) 2016-05-18 2020-12-14 Array Biopharma Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN111094291B (zh) * 2017-08-11 2022-06-21 晟科药业（江苏）有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1636236T3 (pl) 2003-05-22 2014-02-28 Nerviano Medical Sciences Srl Pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz
ES2390237T3 (es) * 2006-02-10 2012-11-07 Nerviano Medical Sciences S.R.L. Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
JP5579715B2 (ja) * 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP2012509859A (ja) * 2008-11-24 2012-04-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 中皮腫の治療のためのｃｄｋ阻害物質

Also Published As

Publication number Publication date
WO2010012733A9 (en) 2011-04-14
JP5677296B2 (ja) 2015-02-25
US20110190311A1 (en) 2011-08-04
JP2011529467A (ja) 2011-12-08
WO2010012733A1 (en) 2010-02-04
EP2323664A1 (en) 2011-05-25
CN102105151A (zh) 2011-06-22
US8946226B2 (en) 2015-02-03
CN102105151B (zh) 2013-12-18
EP2323664B1 (en) 2015-01-07
ES2532732T3 (es) 2015-03-31

Similar Documents

Publication Publication Date Title
HK1153938A1 (en) Use of a cdk inhibitor for the treatment of glioma cdk
HUS1800011I1 (hu) Kombinációs terápia szubsztituált oxazolidinonokkal
HK1214514A1 (zh) 神經浸潤抑制劑
ZA201004859B (en) Use of a gamma-secretase inhibitor for treating cancer
HK1208237A1 (en) Methods for the treatment of gout
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
IL193484A0 (en) Gsk-3 inhibitors for the treatment of osteoporosis
EP2195010A4 (en) TREATMENT WITH INHIBITORS OF KALLIKREINE
EP2272817A4 (en) INHIBITOR OF PAI-1
EP2195011A4 (en) TREATMENT WITH CALLICINE INHIBITORS
GB0823480D0 (en) Devices for the treatment of fluids
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
HK1169408A1 (en) Cdk inhibitor salts cdk
EP2237793A4 (en) INHIBITORS OF CATHEPSIN B
EP2326318A4 (en) SUR1 HEMMER FOR THERAPEUTIC PURPOSES
ZA201008192B (en) A phytosystem for treatment of sewage
ZA201101303B (en) Kit for the treatment of onychomycosis
HK1166795A1 (en) Use of a kinase inhibitor for the treatment of thymoma
IL212924A0 (en) Hsp90 inhibitors for therapeutic treatment
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
IL207247A0 (en) Use of ranolazine for the treatment of cardiovascular disease
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
EP2177529A4 (en) NEW DE-SECRETASE INHIBITOR
IL203599A (en) Mark @ for treatment @ inhibitor @ of @ egfr
EP2459507A4 (en) USE OF ERYTHRITOL FOR THE PREVENTION OR TREATMENT OF HYPERTONIA